PATENTSCOPE will be unavailable a few hours for maintenance reason on Monday 03.02.2020 at 10:00 AM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2009151098) SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING β-SECRETASE-INHIBITING ACTIVITY
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2009/151098 International Application No.: PCT/JP2009/060696
Publication Date: 17.12.2009 International Filing Date: 11.06.2009
IPC:
C07D 417/12 (2006.01) ,A61K 31/4439 (2006.01) ,A61K 31/497 (2006.01) ,A61K 31/541 (2006.01) ,A61P 25/28 (2006.01) ,A61P 43/00 (2006.01) ,C07D 417/10 (2006.01) ,C07D 417/14 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
4427
containing further heterocyclic ring systems
4439
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4965
Non-condensed pyrazines
497
containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
54
having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
541
Non-condensed thiazines containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
28
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43
Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02
containing two hetero rings
10
linked by a carbon chain containing aromatic rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
14
containing three or more hetero rings
Applicants:
塩野義製薬株式会社 SHIONOGI & CO., LTD. [JP/JP]; 大阪府大阪市中央区道修町3丁目1番8号 1-8, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 5410045, JP (AllExceptUS)
堀 章洋 HORI, Akihiro [JP/JP]; JP (UsOnly)
米澤 秀爾 YONEZAWA, Shuji [JP/JP]; JP (UsOnly)
藤越 千明 FUJIKOSHI, Chiaki [JP/JP]; JP (UsOnly)
松本 彩枝 MATSUMOTO, Sae [JP/JP]; JP (UsOnly)
郡山 雄二 KOORIYAMA, Yuuji [JP/JP]; JP (UsOnly)
上野 達彦 UENO, Tatsuhiko [JP/JP]; JP (UsOnly)
加藤 輝和 KATO, Terukazu [JP/JP]; JP (UsOnly)
Inventors:
堀 章洋 HORI, Akihiro; JP
米澤 秀爾 YONEZAWA, Shuji; JP
藤越 千明 FUJIKOSHI, Chiaki; JP
松本 彩枝 MATSUMOTO, Sae; JP
郡山 雄二 KOORIYAMA, Yuuji; JP
上野 達彦 UENO, Tatsuhiko; JP
加藤 輝和 KATO, Terukazu; JP
Agent:
高山 裕貢 TAKAYAMA, Hirotsugu; JP
Priority Data:
2008-15499013.06.2008JP
2008-27168922.10.2008JP
2009-10361622.04.2009JP
Title (EN) SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING β-SECRETASE-INHIBITING ACTIVITY
(FR) DÉRIVÉ HÉTÉROCYCLIQUE CONTENANT DU SOUFRE AYANT UNE ACTIVITÉ INHIBANT LA β-SÉCRÉTASE
(JA) βセクレターゼ阻害作用を有する含硫黄複素環誘導体
Abstract:
(EN) Disclosed are: a compound represented by formula (I), a pharmaceutically acceptable salt of the compound, or a solvate of the compound or the pharmaceutically acceptable salt thereof; and others, which can be used as therapeutic agents for diseases induced by the production, secretion and/or deposition of amyloid-β protein. [In the formula, the ring A represents a carbocyclic group which may have a substituent, or a heterocyclic group which may have a substituent; R1 represents a lower alkyl which may have a substituent, or the like; R2a and R2b independently represent a hydrogen, a lower alkyl which may have a substituent, or the like; and R3a and R3c independently represent a hydrogen, a halogen, a hydroxy, a lower alkyl which may have a substituent, or the like.]
(FR) L’invention concerne un composé représenté par la formule (I), un sel pharmaceutiquement acceptable du composé, ou un solvate du composé ou le sel pharmaceutiquement acceptable de celui-ci; et d’autres composés, qui peuvent être utilisés comme agents thérapeutiques pour des maladies induites par la production, la sécrétion et/ou le dépôt de protéine amyloïde β. [Dans la formule, le cycle A représente un groupe carbocyclique qui peut avoir un substituant, ou un groupe hétérocyclique qui peut avoir un substituant; R1 représente un groupe alkyle inférieur qui peut avoir un substituant, ou analogues; R2a et R2b représentent indépendamment un atome d’hydrogène, un groupe alkyle inférieur qui peut avoir un substituant, ou analogues; et R3a et R3c représentent indépendamment un atome d’hydrogène, un atome d’halogène, un groupe hydroxy, un groupe alkyle inférieur qui peut avoir un substituant, ou analogues.]
(JA) アミロイドβタンパク質の産生、分泌および/または沈着により誘発される疾患の治療剤として、例えば以下の化合物等を提供する。  式(I):(式中、環Aは置換基を有していてもよい炭素環式基または置換基を有していてもよい複素環式基であり、 Rは置換基を有していてもよい低級アルキル等、 R2aおよびR2bは各々独立して水素、置換基を有していてもよい低級アルキル等、 R3aおよびR3cは各々独立して水素、ハロゲン、ヒドロキシ、置換基を有していてもよい低級アルキル等を表す) で示される化合物もしくはその製薬上許容される塩またはそれらの溶媒和物。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)
Also published as:
DZDZP2011000023EP2305672SG167304IL209927MXMX/a/2010/013256US20110190279
CN102119161CA2727859EA201071370KR1020110008100KR1020130018370JP5490692
NZ589590AU2009258496VN25901ID051.0802MYPI 2010005611PH1/2013/500242
PH1/2013/500243IN99/CHENP/2011